Humanized antibodies against CD3
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 3, 2008
Grant Date -
N/A
app pub date -
Jul 18, 2000
filing date -
Mar 27, 1992
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully